ABIVAX Société Anonyme (NASDAQ:ABVX) Sees Unusually-High Trading Volume – Here’s What Happened

ABIVAX Société Anonyme (NASDAQ:ABVX) saw unusually-strong trading volume on Thursday . Approximately 363,981 shares changed hands during trading, an increase of 286% from the previous session’s volume of 94,201 shares.The stock last traded at $10.50 and had previously closed at $10.28.

Analyst Ratings Changes

Separately, Laidlaw assumed coverage on ABIVAX Société Anonyme in a research report on Monday, July 29th. They issued a “buy” rating and a $48.00 price target for the company. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the company’s stock. Based on data from MarketBeat, ABIVAX Société Anonyme presently has a consensus rating of “Moderate Buy” and a consensus price target of $36.50.

ABIVAX Société Anonyme Trading Up 1.2 %

The stock has a 50 day moving average of $11.12 and a 200-day moving average of $12.71.

Institutional Trading of ABIVAX Société Anonyme

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets purchased a new position in ABIVAX Société Anonyme in the 1st quarter worth about $81,000. Capstone Investment Advisors LLC raised its stake in shares of ABIVAX Société Anonyme by 9.0% during the first quarter. Capstone Investment Advisors LLC now owns 62,966 shares of the company’s stock valued at $900,000 after acquiring an additional 5,199 shares in the last quarter. Kennedy Capital Management LLC raised its stake in shares of ABIVAX Société Anonyme by 35.3% during the first quarter. Kennedy Capital Management LLC now owns 120,168 shares of the company’s stock valued at $1,718,000 after acquiring an additional 31,331 shares in the last quarter. Finally, Janus Henderson Group PLC boosted its holdings in shares of ABIVAX Société Anonyme by 18.2% in the first quarter. Janus Henderson Group PLC now owns 851,839 shares of the company’s stock valued at $12,113,000 after purchasing an additional 131,414 shares during the period. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.